目的：系统评价甘精胰岛素对比预混胰岛素治疗2 型糖尿病的疗效与安全性，以为临床提供循证参考。方法：计算机检

索PubMed、中国期刊全文数据库、万方数据库和中文科技期刊数据库，收集甘精胰岛素（试验组）对比预混胰岛素（对照组）治疗2

型糖尿病疗效与安全性的随机对照试验（RCT），对符合纳入标准的临床研究进行资料提取，并采用改良后的Jadad 量表进行质量

评价，采用Rev Man 5.0 统计软件进行Meta 分析。结果：共纳入10 项RCT，合计1 655 例患者。Meta 分析结果显示，甘精胰岛素在

降低糖化血红蛋白水平[MD＝－0.41，95％CI（－0.64，－0.18），P＜0.001]、空腹血糖水平[MD＝－0.51，95％CI（－0.99，－0.02），

P＝0.04]方面均优于预混胰岛素，两组比较差异均有统计学意义，而在降低餐后2 h 血糖水平[MD＝－0.56，95％CI（－1.21，0.09），

P＝0.09]、体质量指数[MD＝－0.52，95％CI（－1.52，0.48），P＝0.31]方面，差异均无统计学意义；甘精胰岛素组患者的低血糖发生

率[RR＝0.65，95％CI（0.46，0.90），P＝0.01]低于预混胰岛素组，差异有统计学意义。结论：甘精胰岛素治疗2 型糖尿病的疗效与安

全性优于预混胰岛素。

OBJECTIVE：To systematically review the efficacy and safety of insulin glargine versus premixed insulin in treatment

of type 2 diabetes，and provide evidence-based reference for clinical treatment. METHODS：Retrieved from PubMed，CJFD，

Wanfang Database and VIP Database，the randomized controlled trials（RCT）about the efficacy and safety of premixed insulin versus

insulin glargine in the treatment of type 2 diabetes were collected. Meta-analysis was performed by using Rev Man 5.0 statistics

software after extracting data and evaluating quality by modified Jadad. RESULTS：A total of 10 RCTs were enrolled，involving 1 655

patients. Results of Meta-analysis showed that insulin glargine was better than premixed insulin on reducing glycated hemoglobin

[M＝－0.41，95％ CI（－0.64，－0.18），P＜0.001] and fasting blood glucose [MD＝－0.51，95％ CI（－0.99，－0.02），P＝0.04]，

there were significantly differences between 2 groups，and there were no significantly differences in reducing 2 h postprandial blood

glucose [MD＝－0.56，95％ CI（－1.21，0.09），P＝0.09] and body mass index [MD＝－0.52，95％ CI（－1.52，0.48），P＝0.31]；the

incidence of hypoglycemia in insulin glargine group was significantly lower than premixed insulin，there were significantly differences

between 2 groups [RR＝0.65，95％CI（0.46，0.90），P＝0.01]. CONCLUSIONS：The efficacy and safety of insulin glargine are

better than premixed insulin in the treatment of type 2 diabetes.